Digital Biology MarketSize, Share & Industry Analysis, 2026-2034By ComponentBy ApplicationBy TechnologyBy End UserBy Deployment ModeBy Biological Data TypeBy Therapeutic AreaBy Therapeutic ModalityBy Business Model
Full title & scope — all 9 axes with their segments
Digital Biology Market Size, Share & Industry Analysis, By Component (Software and Platforms, Services, Hardware and Instruments, Data and Content), By Application (Drug Discovery, Synthetic Biology, Precision Medicine, Clinical Diagnostics, Agricultural Biotechnology, Industrial Biotechnology), By Technology (Artificial Intelligence and Machine Learning, Computational Biology and Bioinformatics, Multi-Omics Analytics, Digital Twins and Biosimulation, Lab Automation and Robotics, Cloud and High-Performance Computing), By End User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Healthcare Providers, Contract Research Organizations, Agricultural Companies), By Deployment Mode (Cloud-Based, On-Premises, Hybrid), By Biological Data Type (Genomic Data, Proteomic Data, Transcriptomic Data, Metabolomic Data, Imaging and Phenotypic Data, Clinical and Real-World Data), By Therapeutic Area (Oncology, Neurology, Infectious Diseases, Immunology and Inflammation, Rare and Genetic Diseases, Metabolic and Cardiovascular Diseases), By Therapeutic Modality (Small Molecules, Biologics and Antibodies, Cell and Gene Therapies, Nucleic Acid Therapeutics, Vaccines), By Business Model (Software Licensing and Subscription, Platform-as-a-Service, Fee-for-Service and Contract Research, Collaboration and Milestone-Based, Data Licensing), and Regional Forecast, 2026-2034
How the estimates were built: data sources, modelling approach and validation steps.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
The market was built upward from the volumes and prices that carry it. Software and platforms are sized from licensed seats, active cloud accounts and subscription tiers multiplied by realised annual contract values. Services come from project counts and day-rate bands in computational discovery and data engineering. Hardware is built from installed bases of sequencers and automated lab systems, with replacement cycles and consumable attach rates applied. Data and content use licensed dataset volumes and access prices. The build was then checked against segment revenue disclosed in company filings. Where the two disagreed, the unit and price assumptions in the build were corrected; disclosed figures were not averaged in.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews target the roles that decide spending in this market: heads of computational biology and informatics at drug developers, research IT and data platform leads, procurement managers for instruments and cloud compute, laboratory automation engineers, and regulatory affairs staff who handle in silico evidence in submissions. Conversations also include platform vendors' product and commercial leads and contract research buyers. Sampling emphasises North America and Europe, where the largest buyer base sits, and adds Asia Pacific, with China, Japan and India given weight because platform adoption is moving fastest there. Questions focus on seat counts, contract values, renewal behaviour, build-versus-buy choices and the share of discovery budgets moving to digital workflows.
Desk research rests on public registers and filings for this market. Biological data volumes are traced through the INSDC sequence archives, the Gene Expression Omnibus, UniProt and the Protein Data Bank. Activity levels come from ClinicalTrials.gov, the FDA and EMA approval and guidance records, and patent filings in computational biology classes. Public research funding is read from NIH RePORTER and Horizon Europe project listings. Supplier revenue comes from SEC 10-K and 20-F filings and company annual reports, and instrument volumes from customs data under HS code 9027. Trade bodies such as the Biotechnology Innovation Organization supply adoption benchmarks.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from adoption of computational methods in discovery and development pipelines, growth in biological data generation, and the price behaviour of software, compute and data access. Each segment is projected from its own unit and price drivers, and drivers are modelled explicitly instead of trended. Cloud compute prices are assumed to fall slowly while contract values rise as platforms add modules. For the forecast to hold, drug developers must keep moving budget from wet-lab screening to in silico work, model outputs must keep being validated in the lab, and data access must stay affordable. The early forecast years normalise for a funding slowdown among venture-backed platform companies.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Outputs were back-tested by running the same unit and price logic over 2020 to 2024 and comparing the implied growth with the recorded movement in supplier filings and public funding. Segment shifts, such as the move toward cloud delivery and the rise of services tied to data engineering, were reviewed with domain specialists. Sensitivities were run on adoption rate, average contract value, compute price and the pace of regulatory acceptance, and each was tested for its effect on the 2034 total and on regional shares. Every axis was reconciled to the market total in both the base year and the final forecast year.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
The estimate is firmest for software, cloud delivery and large pharmaceutical buyers, where supplier filings and contract data give a direct read. It is weaker for data licensing, digital twins and agricultural and industrial uses, where adoption is early, pricing is bespoke and reporting is thin. Many suppliers do not disclose digital biology revenue separately, so the sizing leans on allocation. Definitions of this category vary, so the boundary of what counts is a judgement. A reasonable band around the 2025 figure is plus or minus fifteen percent. Changes in biotech funding, data privacy rules or model validation standards could force a revision.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Digital Biology Market projected to reach?
USD 44.8 USD Billion by 2034, CAGR 15.65%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
North America leads with 42% of global revenue through 2034.
05Which segment leads the market?
Software and Platforms is the largest line by component, at 38% of revenue in 2025.
06Who are the key companies profiled?
Thermo Fisher Scientific Inc., Illumina, Inc., Schrödinger, Inc., Certara, Inc., Dassault Systèmes SE, Insilico Medicine, Recursion Pharmaceuticals, Inc., Exscientia plc, Benchling, Inc., Agilent Technologies, Inc., QIAGEN N.V., Danaher Corporation, Revvity, Inc., Twist Bioscience Corporation, Ginkgo Bioworks Holdings, Inc., Simulations Plus, Inc., Absci Corporation, Evotec SE, Compugen Ltd., BenevolentAI, Genedata AG, Bio-Rad Laboratories, Inc., 10x Genomics, Inc., Pacific Biosciences of California, Inc., Oxford Nanopore Technologies plc, NVIDIA Corporation, Tempus AI, Inc., Dotmatics, Cellarity, Inc.. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.